Evidence map›Paper›PMID 35240689›Full record

ArticleBlood advances2022

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis.

Mengyang Di, Can Cui, Shalin K Kothari, Amer M Zeidan, Nikolai A Podoltsev, Natalia Neparidze, Rory M Shallis, Rong Wang, Xiaomei Ma, Scott F Huntington

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengyang DiSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-6165-2617
Can CuiDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT; and.ORCID 0000-0003-4736-4330
Shalin K KothariSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Nikolai A PodoltsevSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-3657-778X
Natalia NeparidzeSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Rory M ShallisSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-8542-2944
Rong WangYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT.
Xiaomei MaYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT.
Scott F HuntingtonSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-7071-6475

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, Mantle-CellAgammaglobulinaemia Tyrosine KinaseHumansProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseProtein Kinase Inhibitors

Identifiers

PMID35240689
PMCPMC9198937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.